Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.

Autor: Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Albiges L; Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France., Tomczak P; Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland., Suárez C; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Voss MH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Velasco G; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain., Chahoud J; Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Mochalova A; Department of Chemotherapy, Clinical Hospital Number 1 MEDSI, Moscow, Russia., Procopio G; Department of Medical Oncology, Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy., Mahammedi H; Department of Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France., Zengerling F; Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany., Kim C; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea., Osawa T; Department of Urology, Hokkaido University Hospital, Sapporo, Japan., Angel M; Department of Genitourinary Cancer, Instituto Alexander Fleming, Buenos Aires, Argentina., Gupta S; Genentech, South San Francisco, CA, USA., Khan O; Roche Product, Welwyn Garden City, UK., Bergthold G; F Hoffmann-La Roche, Basel, Switzerland., Liu B; Genentech, South San Francisco, CA, USA., Kalaitzidou M; Roche Product, Welwyn Garden City, UK., Huseni M; Genentech, South San Francisco, CA, USA., Scheffold C; Exelixis, Alameda, CA, USA., Powles T; Barts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK., Choueiri TK; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.

Publikováno v: Lancet (London, England) [Lancet] 2023 Jul 15; Vol. 402 (10397), pp. 185-195. Date of Electronic Publication: 2023 Jun 05.

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

Autor: Desai AV; Department of Pediatrics, Section of Hematology/Oncology/Stem Cell Transplantation, University of Chicago Medical Center, Chicago, Illinois, USA., Robinson GW; Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Gauvain K; Pediatric Neuro-Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Basu EM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Macy ME; Pediatric Hematology-Oncology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Maese L; Department of Pediatrics, Division of Hematology/Oncology, University of Utah/Huntsman Cancer Institute, Salt Lake City, Utah, USA., Whipple NS; Pediatric Hematology-Oncology, University of Utah, Salt Lake City, Utah, USA., Sabnis AJ; Division of Pediatric Oncology, Department of Pediatrics, University of California, San Francisco, California, USA., Foster JH; Department of Pediatrics, Hematology-Oncology, Texas Children's Hospital, Houston, Texas, USA., Shusterman S; Pediatric Hematology and Oncology, Dana Farber Cancer Institute/Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA., Yoon J; Department of Pediatrics, University of California San Diego, San Diego, California, USA., Weiss BD; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Abdelbaki MS; Division of Hematology & Oncology, Nationwide Children's Hospital, Columbus, Ohio, USA., Armstrong AE; Division of Pediatric Hematology/Oncology, Washington University School of Medicine, St. Louis, Missouri, USA., Cash T; Pediatric Hematology/Oncology, Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia, USA., Pratilas CA; Department of Oncology, Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Corradini N; Department of Pediatric Hematology and Oncology, Institute of Pediatric Hematology and Oncology (IHOPe), Léon Bérard Cancer Centre, Lyon, France., Marshall LV; Children and Young People's Unit, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK., Farid-Kapadia M; Biometrics Department, F. Hoffmann-La Roche Ltd., Mississauga, Ontario, Canada., Chohan S; PDD Data & Statistical Sciences, F. Hoffmann-La Roche Ltd., Mississauga, Ontario, Canada., Devlin C; Pharma Development Oncology and Hematology, Roche Products Ltd., Welwyn Garden City, UK., Meneses-Lorente G; Pharma Research and Early Development, Roche Products Ltd., Welwyn Garden City, UK., Cardenas A; Clinical Safety, Genentech, Inc., South San Francisco, California, USA., Hutchinson KE; Oncology Biomarker Development, Genentech, Inc., South San Francisco, California, USA., Bergthold G; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Caron H; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Chow Maneval E; Clinical Development, Ignyta, Inc., San Diego, California, USA., Gajjar A; Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Fox E; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Publikováno v: Neuro-oncology [Neuro Oncol] 2022 Oct 03; Vol. 24 (10), pp. 1776-1789.

Towards a Risk-Based Follow-Up Surveillance Imaging Schedule for Children and Adolescents with Low-Grade Glioma.

Autor: Roka, Kleoniki¹ (AUTHOR) nikiroka@med.uoa.gr, Kersbergen, Karina J.² (AUTHOR) a.y.n.schouten@prinsesmaximacentrum.nl, Schouten-van Meeteren, Antoinette Y. N.² (AUTHOR), Avula, Shivaram³ (AUTHOR) shivaram.avula@alderhey.nhs.uk, Sehested, Astrid⁴ (AUTHOR) astrid.marie.sehested@regionh.dk, Otth, Maria^5,6,7 (AUTHOR) maria.otth@ksipisg.ch, Scheinemann, Katrin^5,7 (AUTHOR) katrin.scheineman@kispisg.ch

Publikováno v: Current Oncology. Nov2024, Vol. 31 Issue 11, p7330-7351. 22p.

Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers.

Autor: Schubert NA; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Lowery CD; Eli Lilly and Company, Indianapolis, IN, USA., Bergthold G; Hoffman-La Roche, Basel, Switzerland., Koster J; Department of Oncogenomics, Amsterdam University Medical Centre, Amsterdam, the Netherlands., Eleveld TF; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Rodríguez A; Hoffman-La Roche, Basel, Switzerland., Jones DTW; Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany., Vassal G; Department of Clinical Research, Gustave Roussy, Villejuif, France., Stancato LF; Eli Lilly and Company, Indianapolis, IN, USA., Pfister SM; Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Heidelberg University Hospital, Heidelberg, Germany., Caron HN; Hoffman-La Roche, Basel, Switzerland., Molenaar JJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: j.j.molenaar@prinsesmaximacentrum.nl.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 May; Vol. 130, pp. 168-181. Date of Electronic Publication: 2020 Mar 27.

Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma.

Autor: Yang, Changlin¹ (AUTHOR), Trivedi, Vrunda¹ (AUTHOR), Dyson, Kyle¹ (AUTHOR), Gu, Tongjun² (AUTHOR), Candelario, Kate M.¹ (AUTHOR), Yegorov, Oleg¹ (AUTHOR), Mitchell, Duane A.¹ (AUTHOR) Duane.Mitchell@neurosurgery.ufl.edu

Publikováno v: Genome Medicine. 8/19/2024, Vol. 16 Issue 1, p1-19. 19p.